Timolol maleate Ophthalmic Solution 0.5% BID

DRUG5 trials

Sponsors

Aerie Pharmaceuticals, Santen Inc.

Conditions

GlaucomaOcular HypertensionOpen-angle GlaucomaPrimary Open Angle Glaucoma

Phase 2

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

CompletedNCT04742283

Santen Inc.Ocular Hypertension, Primary Open Angle Glaucoma

Start: 2020-12-17End: 2021-12-07Updated: 2023-06-22

Phase 3

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

CompletedNCT02207491

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2014-07-31End: 2015-03-31Updated: 2018-04-13

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

CompletedNCT02207621

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2014-07-31End: 2016-03-31Updated: 2018-04-06

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

CompletedNCT02246764

Aerie PharmaceuticalsGlaucoma, Ocular Hypertension

Start: 2014-09-30End: 2016-12-31Updated: 2018-04-06

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

CompletedNCT02558374

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2015-09-30End: 2016-12-31Updated: 2018-04-06

Related Papers

Sepetaprost 0.002% Noninferiority vs. Timolol 0.5% in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: ANGEL-2.

2025-03-04

Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study

Journal of Ocular Pharmacology and Therapeutics2022-02-1512 citations